Market closed
Compass Therapeutics/$CMPX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Compass Therapeutics
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
Ticker
$CMPX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
35
Website
CMPX Metrics
BasicAdvanced
$293M
-
-$0.36
1.00
-
Price and volume
Market cap
$293M
Beta
1
52-week high
$4.08
52-week low
$0.77
Average daily volume
2.1M
Financial strength
Current ratio
14.96
Quick ratio
14.28
Long term debt to equity
5.027
Total debt to equity
5.297
Management effectiveness
Return on assets (TTM)
-23.81%
Return on equity (TTM)
-36.07%
Valuation
Price to revenue (TTM)
342.654
Price to book
2.33
Price to tangible book (TTM)
2.33
Price to free cash flow (TTM)
-6.487
Growth
Earnings per share change (TTM)
7.43%
3-year earnings per share growth (CAGR)
-34.97%
What the Analysts think about CMPX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Compass Therapeutics stock.
CMPX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CMPX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CMPX News
AllArticlesVideos
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
GlobeNewsWire·4 days ago
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
GlobeNewsWire·3 weeks ago
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Compass Therapeutics stock?
Compass Therapeutics (CMPX) has a market cap of $293M as of April 25, 2025.
What is the P/E ratio for Compass Therapeutics stock?
The price to earnings (P/E) ratio for Compass Therapeutics (CMPX) stock is 0 as of April 25, 2025.
Does Compass Therapeutics stock pay dividends?
No, Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders as of April 25, 2025.
When is the next Compass Therapeutics dividend payment date?
Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders.
What is the beta indicator for Compass Therapeutics?
Compass Therapeutics (CMPX) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.